Loading...
•
Jun 30, 2022
Rxsight Q2 2022 Earnings Report
RxSight reported strong revenue growth driven by increased sales of LDDs and LALs.
Key Takeaways
RxSight, Inc. reported a significant increase in revenue for the second quarter of 2022, driven by strong demand for its Light Delivery Devices (LDD) and Light Adjustable Lenses (LAL). The company's revenue grew by 132% compared to the same quarter last year. The company has revised its 2022 full year revenue guidance to a range of $44.0 million to $46.0 million.
Revenue for Q2 2022 was $11.4 million, a 132% increase compared to Q2 2021.
49 Light Delivery Devices (LDDs) were sold, a 96% unit increase from Q2 2021, expanding the installed base to 294 LDDs.
5,400 Light Adjustable Lenses (LALs) were sold, a 196% increase in procedure volumes compared to Q2 2021.
Full-year 2022 revenue guidance was increased to a range of $44.0 million to $46.0 million.
Revenue by Segment
Forward Guidance
RxSight has revised its 2022 full year revenue guidance to a range of $44.0 million to $46.0 million. The revised guidance range implies an annual growth rate versus 2021 of 95% to 104%.
Positive Outlook
- Revised 2022 full year revenue guidance to a range of $44.0 million to $46.0 million.
- The revised guidance range implies an annual growth rate versus 2021 of 95% to 104%.
- Increased 2022 gross margin guidance range to 37% to 38% of revenue, up from the previous range of 35% to 36% of revenue.
Challenges Ahead
- Narrowed operating expense guidance to a range of $88.0 million to $90.0 million compared to prior guidance of $86.0 million to $90.0 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...